Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Treprostinil · Remodulin, Tyvaso

Small molecule · Agonist · developed by United Therap

Approved FDA, May 2002
UTHR Developer
7 Registered trials

What is Treprostinil?

Treprostinil is a prostacyclin mimetic that acts on the prostacyclin pathway to cause direct vasodilation of pulmonary and systemic arterial beds and to inhibit platelet aggregation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Remodulin, Tyvaso, Tyvaso Dpi, Yutrepia, L-606
Drug type
Small molecule
Mechanism
Agonist
Pathways
vasodilation of pulmonary and systemic arterial vascular beds, inhibition of platelet aggregation
Therapy area
Cardiovascular, Respiratory
Developer
United Therap (UTHR)
Also in trials of
LQDA, MNKD
FDA status
Approved as Remodulin, Tyvaso, Tyvaso Dpi (May 21, 2002), NDA021272 · FDA label
UNII
RUM6K67ESG

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 2, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05203510 Phase 4 Pulmonary Arterial Hypertension Active not recruiting UTHR
NCT07285655 Phase 3 Pulmonary Hypertension Due to Lung Disease (Disorder) Recruiting LQDA
NCT05943535 Phase 3 Progressive Pulmonary Fibrosis Recruiting UTHR
NCT03794583 Phase 3 Pulmonary Hypertension Terminated UTHR
NCT07037836 Phase 2 COPD (Chronic Obstructive Pulmonary Disease) Recruiting UTHR
NCT04005469 Phase 1/2 Ischemia Reperfusion Injury Recruiting UTHR
NCT03464864 Phase 1 Pulmonary Arterial Hypertension Completed MNKD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COPD (Chronic Obstructive Pulmonary Disease)HypoxemiaInterstitial Lung DiseaseProgressive Pulmonary FibrosisPulmonary Hypertension Due to Lung Disease (Disorder)Chronic Obstructive Pulmonary DiseasePulmonary Arterial HypertensionPulmonary Hypertension

More from United Therap

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the UTHR page.

Follow UTHR, the company behind Treprostinil

See UTHR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

UTHR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.